AGITATION
Clinical trials for AGITATION explained in plain language.
Never miss a new study
Get alerted when new AGITATION trials appear
Sign up with your email to follow new studies for AGITATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can acupressure calm ventilator patients? new trial investigates
Symptom relief CompletedThis study tests whether repeated acupressure can help reduce agitation, pain, and sleep disturbances in intensive care unit (ICU) patients who are on mechanical ventilators. Participants receive either real acupressure or a light touch (sham) twice daily for four days. Researche…
Matched conditions: AGITATION
Phase: NA • Sponsor: Yang Yun Shiuan • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New dissolving film could calm agitation in schizophrenia without needles
Symptom relief CompletedThis Phase 3 trial tested a sublingual film containing dexmedetomidine (BXCL501) to quickly reduce agitation in 380 adults with schizophrenia or related disorders. Participants received either the drug or a placebo film, and researchers measured changes in agitation symptoms over…
Matched conditions: AGITATION
Phase: PHASE3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Can a common sedative calm ICU delirium without a breathing tube?
Symptom relief CompletedThis study tested whether the sedative dexmedetomidine can reduce how long non-intubated ICU patients experience agitated delirium. Researchers randomly gave 168 patients either dexmedetomidine or a placebo. The goal was to see if the drug shortens agitation and delirium, and red…
Matched conditions: AGITATION
Phase: PHASE3 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New drug calms dementia agitation in phase 3 trial
Symptom relief CompletedThis study tested a medicine called BXCL501 for calming sudden episodes of agitation in people with dementia. It involved 151 participants who took the medicine only when needed over 12 weeks. The goal was to see if it safely reduces severe restlessness, tension, or aggression.
Matched conditions: AGITATION
Phase: PHASE3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Hope for Alzheimer's agitation: new drug shows promise in major trial
Symptom relief CompletedThis study tested an experimental drug called AXS-05 to see if it can safely reduce agitation in people with Alzheimer's disease. About 408 participants took either the drug or a placebo for several weeks. The goal was to measure changes in agitation using a standard rating scale…
Matched conditions: AGITATION
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC